Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
Year: 2023
Type: article
Study design: Clinical Trial
Source: The Lancet Haematology
Authors: Thomas Pabst, Cristina Papayannidis, Fatih Demirkan, Vadim Doronin, Laura M Fogliatto, Christina Guttke, Emmanuel Gyan, Nada Hamad, Pilar Herrera, Anna Hultberg, Julie Jacobs, Amy J Johnson, Angélique Langlois, Xuewen Ma, Giovanni Martinelli, Montserrat Arnan, Rouven Müller, Kerri Nottage, Yishai Ofran, Muhit Özcan, Olga Samoilova, Jaszianne A Tolbert, Géralyn C Trudel, Liang Xiu, Norbert Vey, Andrew H Wei
Institutions: University Hospital of Bern, Istituto di Ematologia di Bologna, Dokuz Eylül University, Moscow Multidisciplinary Clinical Center "Kommunarka", Universidade Federal do Rio Grande do Sul, Centre Hospitalier Universitaire de Tours, UNSW Sydney, St Vincent's Hospital Sydney, Hospital Universitario Ramón y Cajal, Argenx (Belgium), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, University Hospital Zurich, Janssen Research & Development (United States), Hebrew University of Jerusalem, Shaare Zedek Medical Center, Bikur Cholim Hospital, Ankara University, Nizhny Novgorod Regional Clinical Hospital named after Semashko, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, The Royal Melbourne Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, The Alfred Hospital, Monash University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: Janssen Research and Development
OpenAlex ID: W4388031558
